Oral
Oral capability covers prevention, rapid point-of-care diagnostics, infection control, trauma management, and rehabilitation for dental and maxillofacial injuries. It addresses oral-systemic interactions (sepsis risk, airway compromise), antimicrobial resistance and biofilms, prosthetic and soft-tissue reconstruction, and technologies tailored for austere or prolonged-field-care environments.
Technical Challenges
Acute dental and maxillofacial trauma (blast, penetrating, blunt) with airway and hemorrhage risks in polytrauma.
Biofilm formation and antimicrobial resistance complicating oral wound and implant infections.
Limited point-of-care diagnostics for oral pathogens and differentiation of colonization versus invasive infection.
Constraints of prolonged-field care: limited sterilization, power, imaging, and specialist surgical support.
Emerging Opportunities
Rapid, rugged, point-of-care tests for oral pathogens and antibiotic-resistance markers suitable for field use.
Antimicrobial coatings and wound dressings effective in saliva and contaminated oral environments.
Portable imaging and surgical tools for diagnosis and stabilization of mandibular, dental, and facial fractures.
Regenerative bone and soft-tissue solutions that enable reconstruction without sophisticated surgical suites.
Current and Emerging Technologies in Oral
Point-of-care molecular and host-response diagnostics
Rapid PCR/CRISPR and antigen platforms, combined with host-biomarker panels, to detect oral pathogens, virulence factors, and early systemic inflammatory responses at the point of injury.
Antimicrobial agents, coatings and anti-biofilm strategies
Novel antimicrobials, surface-modified implants, and enzymatic or nanoparticle approaches that disrupt biofilms and address multidrug-resistant organisms in oral wounds and prostheses.
Portable imaging, intraoral 3D scanning, and augmented surgical navigation
Low-power cone-beam CT, handheld ultrasound, and compact intraoral scanners to enable on-site diagnosis, fracture assessment, and preoperative planning in forward environments.
Regenerative biomaterials and point-of-care grafting
Osteoinductive scaffolds, growth-factor–enhanced matrices, and off-the-shelf constructs to support jaw bone and soft tissue reconstruction when evacuation is delayed.
Tele-dentistry, decision support, and AI triage
Secure telehealth platforms, image-forward consultation, and AI tools to prioritize cases, guide non-specialist providers, and integrate oral data with trauma care workflows.
Importance to Military Medicine
Combat casualty care
Oral and maxillofacial injuries can threaten airway patency, cause hemorrhage, and complicate polytrauma—requiring immediate diagnostics and stabilization.
Prolonged and austere care
Delayed evacuation elevates infection and loss-of-function risk; field-capable oral solutions sustain warfighter health until definitive care.
Force readiness and prevention
Dental readiness impacts deployability; prevention, surveillance, and rapid treatment preserve operational capability.
Civilian and dual-use impact
Technologies developed for military oral trauma and infection translate to civilian trauma centers, under-resourced clinics, and disaster response.
Alignment with the MTEC Mission
Directly advances MTEC priorities by accelerating field-ready diagnostics, therapeutics, and regenerative solutions for warfighter survival and recovery.
Supports interdisciplinary approaches across combat casualty care, infectious disease, and prolonged care portfolios emphasized by MTEC.
Enables dual-use innovations that benefit civilian healthcare while meeting DoD readiness and austere-environment requirements.
Dual-Use (Military + Civilian) Applications
Forward-deployable dental kits and hemorrhage-control products for immediate stabilization of oral bleeding and airway threats.
Point-of-care pathogen testing to guide antimicrobial selection and reduce inappropriate antibiotic use in field conditions.
Portable imaging and tele-dentistry to triage fractures, plan temporary fixation, and coordinate evacuation priorities.
Regenerative scaffolds and off-the-shelf grafts enabling reconstructive interventions when definitive surgery is delayed.
Explore MTEC Members with Oral Capabilities
MTEC members contribute expertise across diagnostics, biomaterials, device miniaturization, and clinical trial networks to translate oral technologies rapidly into practice.
Consortium collaboration accelerates integration of military requirements, regulatory strategy, and civilian partnerships to validate dual-use solutions.
Explore member profiles to identify partners with clinical, engineering, and commercialization capabilities ready to advance oral health innovations for warfighters and civilians.
88 Members with Oral capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
ETC Innovation is a vertically integrated MedTech development company specializing in the design, development, and manufacturing of advanced wound dressing materials, antimicrobial substrates, and infection control products. The company brings together expertise in materials science, manufacturing processes, and regulatory compliance, offering solutions from concept through production for the medical industry. ETC Innovation operates a US-based facility supporting pilot to commercial-scale production, with a focus on custom materials for wound care and infection control. The company invests in R&D and holds equity in several early-stage medical device companies, and it provides proprietary material formulations, process development, and confidential research partnerships.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.
Revagenix is a precision-therapeutics company specializing in the discovery and development of targeted medicines for serious chronic diseases, with a primary focus on respiratory conditions such as non-cystic fibrosis bronchiectasis. Leveraging a biology-driven, first-principles approach, the company engineers therapies optimized for disease biology, patient need, and real-world delivery requirements. The team brings experience spanning the entire drug lifecycle from discovery through commercialization and collaborates closely with public and private partners to accelerate advancement from early-stage science to clinical development.
CA Analytical Testing Services is an FDA inspected contract laboratory and drug development partner providing integrated analytical, microbiological, formulation, and CMC support across the product lifecycle. We can integrate directly into development programs to provide analytical method development, microbiological support, formulation and characterization activities, and problem-solving throughout early- and late-stage development. Beyond laboratory testing, CA Analytical can support broader drug and medical device programs through CDMO selection and qualification, technology transfer, third-party quality and manufacturing oversight, regulatory support, QC release testing, and stability programs. Our team can function as an extension of a sponsor's internal development and quality organization, helping coordinate technical activities across multiple external partners. CA Analytical is also building an internal drug product portfolio that includes small-molecule and liposomal formulations. We are particularly interested in partnering with organizations developing novel or alternative drug-delivery technologies that can be combined with existing or emerging therapeutics to improve delivery, durability, usability, and ultimately advance medicines toward clinical application.
Limax Biosciences is dedicated to revolutionizing tissue healing through innovative biomaterials inspired by the natural slime of slugs. Their hydrogels provide superior adhesion and healing capabilities, addressing unmet medical needs both inside and outside the body.

Moonrise Medical
Automated Portable Ultrasound for Rapid Vascular Assessment in Combat Casualty Care: Moonrise Medical Inc.
Moonrise Medical Inc. is developing an automated portable ultrasound system for rapid vascular assessment and real-time blood-flow monitoring in combat casualty care. The project is supported through MTEC Award No. 24-01-MPAI-149.
NIRSense
Rugged Physiological Monitoring for the Modern Warfighter: NIRSense
Under MTEC-21-10-NavyMultiTopic, NIRSense is advancing its tactical jet physiological monitoring technology for broader Navy applications. The project focuses on ruggedized, wireless physiological sensors that can provide reliable, real-time insight into warfighter health and performance in demanding operational environments.
Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.